BioSpace News Archive

A potential treatment for listeriosis has been found to be promising in Praedicare’s hollow fiber preclinical model of the disease, caused by the bacteria Listeria monocytogenes.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that it has entered into an agreement with Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD).

Gannex Pharma Co., Ltd. (“Gannex”), a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) today announces that it has completed the first subject dosing in the U.S. drug-drug interaction (DDI) study of Farnesoid X receptor (FXR) agonist ASC42 for treatment of primary biliary cholangitis (PBC).

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at a public offering price of $7.82 per share.

Halozyme Therapeutics, Inc., a leader in converting IV biologics to subcutaneous delivery, announced the pricing of $625.0 million aggregate principal amount of convertible senior notes due 2028.

Endure Biotherapeutics, Inc., a leader in the field of engineered microbial therapeutics with the goal of treating gastrointestinal and metabolic disorders, announced the publication of the seminal paper from the laboratory of Amir Zarrinpar, MD, PhD, assistant professor of medicine at UC San Diego, Endure Bio founder and Chief Medical Officer.

According to Precedence Research, the global microbiome therapeutics market size was estimated at around USD 84.3 million in 2021 and it is projected to hit around USD 973.86 million by 2030, growing at a CAGR of 31.24% from 2022 to 2030

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results for the quarter ended June 30, 2022.

Acer Therapeutics Inc. (Nasdaq: ACER), today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.